Publication

Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma

Fu, L., Cheng, Z., Dong, F., Quan, L., Cui, L., Liu, Y., Zeng, T., Huang, W., Chen, J., Pang, Y., Ye, X., Wu, G., Qian, T., Chen, Y. & Si, C., 2020, In : Journal of Breast Cancer. 11, 5, p. 1182-1194 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Fu, L., Cheng, Z., Dong, F., Quan, L., Cui, L., Liu, Y., ... Si, C. (2020). Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma. Journal of Breast Cancer, 11(5), 1182-1194. https://doi.org/10.7150/jca.37313

Author

Fu, Lin ; Cheng, Zhiheng ; Dong, Fen ; Quan, Liang ; Cui, Longzhen ; Liu, Yan ; Zeng, Tiansheng ; Huang, Wenhui ; Chen, Jinghong ; Pang, Ying ; Ye, Xu ; Wu, Guangsheng ; Qian, Tingting ; Chen, Yang ; Si, Chaozeng. / Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma. In: Journal of Breast Cancer. 2020 ; Vol. 11, No. 5. pp. 1182-1194.

Harvard

Fu, L, Cheng, Z, Dong, F, Quan, L, Cui, L, Liu, Y, Zeng, T, Huang, W, Chen, J, Pang, Y, Ye, X, Wu, G, Qian, T, Chen, Y & Si, C 2020, 'Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma', Journal of Breast Cancer, vol. 11, no. 5, pp. 1182-1194. https://doi.org/10.7150/jca.37313

Standard

Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma. / Fu, Lin; Cheng, Zhiheng; Dong, Fen; Quan, Liang; Cui, Longzhen; Liu, Yan; Zeng, Tiansheng; Huang, Wenhui; Chen, Jinghong; Pang, Ying; Ye, Xu; Wu, Guangsheng; Qian, Tingting; Chen, Yang; Si, Chaozeng.

In: Journal of Breast Cancer, Vol. 11, No. 5, 2020, p. 1182-1194.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Fu L, Cheng Z, Dong F, Quan L, Cui L, Liu Y et al. Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma. Journal of Breast Cancer. 2020;11(5):1182-1194. https://doi.org/10.7150/jca.37313


BibTeX

@article{df270280ff3142a581de1b5e272b45b9,
title = "Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma",
abstract = "Background: Multiple myeloma (MM) is the second most common hematologic malignancy worldwide and does not have sufficient prognostic indicators. FCER1G (Fc fragment Of IgE receptor Ig) is located on chromosome 1q23.3 and is involved in the innate immunity. Early studies have shown that FCER1G participates in many immune-related pathways encompassing multiple cell types. Meanwhile, it is associated with many malignancies. However, the relationship between MM and FCER1G has not been studied.Methods: In this study, we integrated nine independent gene expression omnibus (GEO) datasets and analyzed the associations of FCER1G expression and myeloma progression, ISS stage, 1q21 amplification and survival in 2296 myeloma patients and 48 healthy donors.Results: The expression of FCER1G showed a decreasing trend with the advance of myeloma. As ISS stage and 1q21 amplification level increased, the expression of FCER1G decreased (P = 0.0012 and 0.0036, respectively). MM patients with high FCER1G expression consistently had longer EFS and OS across three large sample datasets (EFS: P = 0.0057, 0.0049, OS: P = 0.0014, 0.00065, 0.0019 and 0.0029, respectively). Meanwhile, univariate and multivariate analysis indicated that high FCER1G expression was an independent favorable prognostic factor for EFS and OS in MM patients (EFS: P = 0.006, 0.027, OS: P =0.002,0.025, respectively).Conclusions: The expression level of FCER1G negatively correlated with myeloma progression, and high FCER1G expression may be applied as a favorable biomarker in MM patients.",
keywords = "Multiple myeloma, FCER1G, Prognosis, Gene expression profile, Bioinformatics analysis, PLASMA-CELL LEUKEMIA, GAMMA-SUBUNIT, GENES, RECEPTOR, POLYMORPHISMS, FCGR2A, CLASSIFICATION, ASSOCIATION, ACTIVATION, INHIBITOR",
author = "Lin Fu and Zhiheng Cheng and Fen Dong and Liang Quan and Longzhen Cui and Yan Liu and Tiansheng Zeng and Wenhui Huang and Jinghong Chen and Ying Pang and Xu Ye and Guangsheng Wu and Tingting Qian and Yang Chen and Chaozeng Si",
year = "2020",
doi = "10.7150/jca.37313",
language = "English",
volume = "11",
pages = "1182--1194",
journal = "Journal of Breast Cancer",
issn = "1738-6756",
publisher = "IVYSPRING INT PUBL",
number = "5",

}

RIS

TY - JOUR

T1 - Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma

AU - Fu, Lin

AU - Cheng, Zhiheng

AU - Dong, Fen

AU - Quan, Liang

AU - Cui, Longzhen

AU - Liu, Yan

AU - Zeng, Tiansheng

AU - Huang, Wenhui

AU - Chen, Jinghong

AU - Pang, Ying

AU - Ye, Xu

AU - Wu, Guangsheng

AU - Qian, Tingting

AU - Chen, Yang

AU - Si, Chaozeng

PY - 2020

Y1 - 2020

N2 - Background: Multiple myeloma (MM) is the second most common hematologic malignancy worldwide and does not have sufficient prognostic indicators. FCER1G (Fc fragment Of IgE receptor Ig) is located on chromosome 1q23.3 and is involved in the innate immunity. Early studies have shown that FCER1G participates in many immune-related pathways encompassing multiple cell types. Meanwhile, it is associated with many malignancies. However, the relationship between MM and FCER1G has not been studied.Methods: In this study, we integrated nine independent gene expression omnibus (GEO) datasets and analyzed the associations of FCER1G expression and myeloma progression, ISS stage, 1q21 amplification and survival in 2296 myeloma patients and 48 healthy donors.Results: The expression of FCER1G showed a decreasing trend with the advance of myeloma. As ISS stage and 1q21 amplification level increased, the expression of FCER1G decreased (P = 0.0012 and 0.0036, respectively). MM patients with high FCER1G expression consistently had longer EFS and OS across three large sample datasets (EFS: P = 0.0057, 0.0049, OS: P = 0.0014, 0.00065, 0.0019 and 0.0029, respectively). Meanwhile, univariate and multivariate analysis indicated that high FCER1G expression was an independent favorable prognostic factor for EFS and OS in MM patients (EFS: P = 0.006, 0.027, OS: P =0.002,0.025, respectively).Conclusions: The expression level of FCER1G negatively correlated with myeloma progression, and high FCER1G expression may be applied as a favorable biomarker in MM patients.

AB - Background: Multiple myeloma (MM) is the second most common hematologic malignancy worldwide and does not have sufficient prognostic indicators. FCER1G (Fc fragment Of IgE receptor Ig) is located on chromosome 1q23.3 and is involved in the innate immunity. Early studies have shown that FCER1G participates in many immune-related pathways encompassing multiple cell types. Meanwhile, it is associated with many malignancies. However, the relationship between MM and FCER1G has not been studied.Methods: In this study, we integrated nine independent gene expression omnibus (GEO) datasets and analyzed the associations of FCER1G expression and myeloma progression, ISS stage, 1q21 amplification and survival in 2296 myeloma patients and 48 healthy donors.Results: The expression of FCER1G showed a decreasing trend with the advance of myeloma. As ISS stage and 1q21 amplification level increased, the expression of FCER1G decreased (P = 0.0012 and 0.0036, respectively). MM patients with high FCER1G expression consistently had longer EFS and OS across three large sample datasets (EFS: P = 0.0057, 0.0049, OS: P = 0.0014, 0.00065, 0.0019 and 0.0029, respectively). Meanwhile, univariate and multivariate analysis indicated that high FCER1G expression was an independent favorable prognostic factor for EFS and OS in MM patients (EFS: P = 0.006, 0.027, OS: P =0.002,0.025, respectively).Conclusions: The expression level of FCER1G negatively correlated with myeloma progression, and high FCER1G expression may be applied as a favorable biomarker in MM patients.

KW - Multiple myeloma

KW - FCER1G

KW - Prognosis

KW - Gene expression profile

KW - Bioinformatics analysis

KW - PLASMA-CELL LEUKEMIA

KW - GAMMA-SUBUNIT

KW - GENES

KW - RECEPTOR

KW - POLYMORPHISMS

KW - FCGR2A

KW - CLASSIFICATION

KW - ASSOCIATION

KW - ACTIVATION

KW - INHIBITOR

U2 - 10.7150/jca.37313

DO - 10.7150/jca.37313

M3 - Article

VL - 11

SP - 1182

EP - 1194

JO - Journal of Breast Cancer

JF - Journal of Breast Cancer

SN - 1738-6756

IS - 5

ER -

ID: 119038716